BRAF and colorectal carcinoma: Triplet regimens containing dabrafenib plus trametinib plus cetuximab, or panitumumab and encorafenib plus binimetinib plus cetuximab or panitumumab were removed as treatment options for BRAF-mutated CRC, based on recommendations resulting from the recent BEACON CRC trial [34].